180 related articles for article (PubMed ID: 38625662)
1. Targeting KRAS
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 Apr; ():. PubMed ID: 38625662
[TBL] [Abstract][Full Text] [Related]
2. Activity and resistance to KRAS
Ye W; Lu X; Qiao Y; Ou WB
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
[TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS in Non-Small Cell Lung Cancer.
Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
Front Oncol; 2021; 11():792635. PubMed ID: 35083149
[TBL] [Abstract][Full Text] [Related]
4. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
Karachaliou A; Kotteas E; Fiste O; Syrigos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
9. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
10. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
12. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
[TBL] [Abstract][Full Text] [Related]
13. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
15.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
16. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
Palma G; Khurshid F; Lu K; Woodward B; Husain H
NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
[TBL] [Abstract][Full Text] [Related]
17. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
18. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
Iska S; Alley EW
Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
[TBL] [Abstract][Full Text] [Related]
19. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.
O'Sullivan É; Keogh A; Henderson B; Finn SP; Gray SG; Gately K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980522
[TBL] [Abstract][Full Text] [Related]
20. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E; Epistolio S; Dazio G; Cefalì M; Wannesson L; Frattini M; Froesch P
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]